Assertion: erythromycin | /r/HasProperty | systemic
Facets:
Source sentences:
text: Amiodarone: May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: Astemizole: May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: Cisapride: May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: Cobicistat: May increase the serum concentration of Erythromycin (Systemic).
text: Dronedarone: May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: QT-prolonging Miscellaneous Agents (Highest Risk): May enhance the QTc-prolonging effect of Erythromycin (Systemic).
text: Sirolimus may increase the serum concentration of Erythromycin (Systemic).
text: Erythromycin (Systemic)
text: Alfentanil: Erythromycin (Systemic) may increase the serum concentration of Alfentanil.
text: ALPRAZolam: Erythromycin (Systemic) may increase the serum concentration of ALPRAZolam.
text: Erythromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone.
text: Erythromycin (Systemic) may increase the serum concentration of Amiodarone.
text: Erythromycin (Systemic) may enhance the QTc-prolonging effect of Astemizole.
text: Erythromycin (Systemic) may increase the serum concentration of Astemizole.
text: AtorvaSTATin: Erythromycin (Systemic) may increase the serum concentration of AtorvaSTATin.
text: Barnidipine: Erythromycin (Systemic) may increase the serum concentration of Barnidipine.
text: Erythromycin (Systemic) may increase the serum concentration of BusPIRone.
text: Erythromycin (Systemic) may increase the serum concentration of CarBAMazepine.
text: Erythromycin (Systemic) may enhance the QTc-prolonging effect of Cisapride.
text: Erythromycin (Systemic) may increase the serum concentration of Cisapride.
text: Clindamycin (Topical): Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical).
text: Clopidogrel: Erythromycin (Systemic) may diminish the antiplatelet effect of Clopidogrel.
text: CycloSPORINE (Systemic): Erythromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).
text: Doxofylline: Erythromycin (Systemic) may increase the serum concentration of Doxofylline.
text: Erythromycin (Systemic) may increase the serum concentration of Dronedarone.
text: Edoxaban: Erythromycin (Systemic) may increase the serum concentration of Edoxaban.
text: Fexofenadine: Erythromycin (Systemic) may increase the serum concentration of Fexofenadine.
text: Fluconazole may increase the serum concentration of Erythromycin (Systemic).
text: Lincomycin: Erythromycin (Systemic) may diminish the therapeutic effect of Lincomycin.
text: Lovastatin: Erythromycin (Systemic) may increase the serum concentration of Lovastatin.
text: Lumacaftor and Ivacaftor: May decrease the serum concentration of Erythromycin (Systemic).
text: Mequitazine: Erythromycin (Systemic) may enhance the arrhythmogenic effect of Mequitazine.
text: Oxybutynin: Erythromycin (Systemic) may increase the serum concentration of Oxybutynin.
text: Pitavastatin: Erythromycin (Systemic) may increase the serum concentration of Pitavastatin.
text: Pivmecillinam: Erythromycin (Systemic) may diminish the therapeutic effect of Pivmecillinam.
text: Pravastatin: Erythromycin (Systemic) may increase the serum concentration of Pravastatin.
text: Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).
text: Erythromycin (Systemic) may increase the serum concentration of QT-prolonging Class IA Antiarrhythmics (Highest Risk).
text: Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).
text: Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).
text: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).
text: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).
text: QuiNIDine: Erythromycin (Systemic) may enhance the QTc-prolonging effect of QuiNIDine.
text: Erythromycin (Systemic) may increase the serum concentration of QuiNIDine.
text: Repaglinide: Erythromycin (Systemic) may increase the serum concentration of Repaglinide.
text: Rivaroxaban: Erythromycin (Systemic) may increase the serum concentration of Rivaroxaban.
text: Saquinavir: Erythromycin (Systemic) may enhance the QTc-prolonging effect of Saquinavir.
text: Erythromycin (Systemic) may increase the serum concentration of Saquinavir.
text: Sertraline: Erythromycin (Systemic) may enhance the adverse/toxic effect of Sertraline.
text: Sildenafil: Erythromycin (Systemic) may increase the serum concentration of Sildenafil.
text: Simeprevir: Erythromycin (Systemic) may increase the serum concentration of Simeprevir.
text: Simeprevir may increase the serum concentration of Erythromycin (Systemic).
text: Simvastatin: Erythromycin (Systemic) may increase the serum concentration of Simvastatin.
text: Sirolimus: Erythromycin (Systemic) may increase the serum concentration of Sirolimus.
text: Tacrolimus (Systemic): Erythromycin (Systemic) may increase the serum concentration of Tacrolimus (Systemic).
text: Zafirlukast: Erythromycin (Systemic) may decrease the serum concentration of Zafirlukast.